Blue Jet Healthcare reported an 8% revenue drop and an 18.8% profit decline for FY26. The company proposed a ₹1.20 dividend but faces a ₹193.39 crore tax demand and project delays.
Blue Jet Healthcare FY26 Results Show Revenue and Profit Decline
Blue Jet Healthcare's revenue from operations for FY26 stood at ₹947.32 crore, an 8% decrease from ₹1,029.99 crore in FY25. Net profit for FY26 was ₹247.82 crore, down 18.8% from ₹305.20 crore in the previous year.
Reader Takeaway: Revenue and profit contraction noted; contingent tax liability and project delays are key concerns.
What just happened
Blue Jet Healthcare has announced its financial results for the fiscal year ended March 31, 2026. The company's revenue from operations saw an 8.0% decline, falling to ₹947.32 crore from ₹1,029.99 crore in the previous fiscal year. Net profit also experienced a significant drop of 18.8%, coming in at ₹247.82 crore compared to ₹305.20 crore in FY25.
The company's board has proposed a final dividend of ₹1.20 per equity share, subject to shareholder approval at the Annual General Meeting.
Why this matters
The decline in revenue and profit signals potential headwinds for the company. Investors will be closely watching the factors contributing to this downturn and the management's strategies to reverse the trend. The proposed dividend, however, indicates a continued focus on returning value to shareholders despite the financial performance.
The backstory
For the fiscal year 2025-26, Blue Jet Healthcare's total assets grew by 15.8% to ₹1,641.16 crore from ₹1,417.53 crore in FY24-25, indicating expansion in its asset base. However, this expansion coincides with a contraction in top-line and bottom-line figures.
What changes now
Investors need to assess the impact of a significant contingent tax liability and project-related challenges. The company is contesting a demand notice for ₹193.39 crore (including interest) related to assessment years 2020-21 to 2023-24. Additionally, the backward integration project at Mahad is facing cost overruns and delays due to process changes, design modifications, and equipment delivery issues.
Risks to watch
A major risk is the contingent tax liability of ₹193.39 crore, which could lead to a substantial financial outflow if the company's appeal is unsuccessful. Delays and cost overruns in the Mahad project could impact future efficiency and capacity ramp-up. Furthermore, internal audit observations highlighted a need to strengthen documentation for identified risks and controls, pointing to potential governance process improvements.
Peer comparison
While specific peer financial data for FY26 is not provided in the filing, the reported revenue and profit declines for Blue Jet Healthcare warrant a comparison with industry averages and key competitors in the pharmaceutical and chemical sectors once their results are available.
Context metrics (time-bound)
Revenue from operations for FY26: ₹947.32 crore (down 8.0% YoY).
Net profit for FY26: ₹247.82 crore (down 18.8% YoY).
Total assets as of FY26: ₹1,641.16 crore (up 15.8% YoY).
Proposed dividend: ₹1.20 per equity share.
Contingent tax liability: ₹193.39 crore.
Capital work-in-progress: ₹301.38 crore.
What to track next
Investors should closely monitor the progress of the tax litigation, the resolution of the Mahad project's delays and cost overruns, and any improvements in the company's internal control documentation processes.